Report copyright - Immunotherapy in advanced NSCLC patients Changing the ... · 5y . OS with Nivolumab in phase I trial. PD-L1 > 50% (N=13) 5-yOS: 43%. Nivolumab up to 96 weeks. Gettinger – JCO 2018
Please pass captcha verification before submit form